GlassScriptPhysician profile
Casey Murphey Lubner
NPI 1205331071
$3,962.71
in general payments reported to CMS, 2019-2025
23 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $207 · 2023: $1,143 · 2024: $1,573 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,576 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,576.25 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $767.56 | 2022-2025 | |
| Janssen Biotech, INC. | $462.16 | 2023-2025 | Tremfya |
| Galderma Laboratories, L.P. | $309.61 | 2022-2025 | Aklief, Nemluvio, Dysport |
| Incyte Corporation | $261.91 | 2024-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $247.68 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $227.87 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $216.75 | 2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $200.00 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $197.10 | 2022-2024 | Arazlo, Jublia, Duobrii |
| Regeneron Healthcare Solutions, INC. | $195.82 | 2023-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $186.78 | 2023-2025 | |
| Ucb, INC. | $155.21 | 2023-2024 | Bimzelx, Cimzia |
| Journey Medical Corporation | $108.52 | 2022-2023 | |
| Arcutis Biotherapeutics, INC. | $91.80 | 2025 | Zoryve |
| Pfizer INC. | $59.91 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $54.04 | 2023-2024 | Otezla |
| Verrica Pharmaceuticals INC. | $51.81 | 2025 | Ycanth |
| Dermavant Sciences, INC. | $42.86 | 2022-2024 | Vtama |
| Strata Skin Sciences, INC. | $33.30 | 2025 | Xtrac |
| Mayne Pharma Commercial LLC | $32.38 | 2023-2025 | |
| Genzyme Corporation | $27.05 | 2023 | |
| Botanix Sb INC | $16.72 | 2025 | Sofdra |
| Almirall LLC | $15.87 | 2023 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Lubner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.